These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36877344)

  • 1. The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells.
    Abutorabi ES; Poursheikhani A; Kashani B; Shamsaiegahkani S; Haghpanah V; Bashash D; Mousavi SA; Momeny M; Ghaffari SH
    Mol Biol Rep; 2023 May; 50(5):4073-4082. PubMed ID: 36877344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
    Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
    Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells.
    Seyed Abutorabi E; Irani S; Yaghmaie M; Ghaffari SH
    Rep Biochem Mol Biol; 2020 Jan; 8(4):438-445. PubMed ID: 32582803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
    Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
    J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle.
    Turkmen E; Sogutlu F; Erdogan M; Biray Avci C
    Med Oncol; 2023 Jun; 40(7):196. PubMed ID: 37284891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
    Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
    Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
    [No Abstract]   [Full Text] [Related]  

  • 8. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway.
    Hu Y; Wen Q; Cai Y; Liu Y; Ma W; Li Q; Song F; Guo Y; Zhu L; Ge J; Zeng Q; Wang J; Yin C; Zheng G; Ge M
    Phytomedicine; 2023 Jan; 108():154528. PubMed ID: 36343549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.
    Allegri L; Baldan F; Mio C; Puppin C; Russo D; Kryštof V; Damante G
    Oncol Rep; 2016 Apr; 35(4):2413-8. PubMed ID: 26884249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.
    Haghpanah V; Fallah P; Tavakoli R; Naderi M; Samimi H; Soleimani M; Larijani B
    Tumour Biol; 2016 Jan; 37(1):1299-308. PubMed ID: 26289851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
    Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
    Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
    Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
    Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking CDK7-Mediated NOTCH1-cMYC Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
    Doolittle WKL; Zhao L; Cheng SY
    Thyroid; 2022 Aug; 32(8):937-948. PubMed ID: 35822558
    [No Abstract]   [Full Text] [Related]  

  • 15. PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer.
    Zhu W; Xie B
    Cancer Biol Ther; 2023 Dec; 24(1):2223383. PubMed ID: 37351847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin.
    Pan Y; Liu P; Chen D; Dou L
    Cancer Biomark; 2017; 18(4):357-366. PubMed ID: 28128736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nutraceuticals on anaplastic thyroid cancer cells.
    Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-Regulation of the Mammalian Target of Rapamycin (mTOR) Pathway Mediates the Effects of the Paeonol-Platinum(II) Complex in Human Thyroid Carcinoma Cells and Mouse SW1736 Tumor Xenografts.
    He L; Guo S; Zhu T; Chen C; Xu K
    Med Sci Monit; 2020 Jun; 26():e922561. PubMed ID: 32594094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
    Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
    Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.